Patient access scheme swings NICE yes for Amgen's Nplate?
This article was originally published in Scrip
Executive Summary
In a change of heart, NICE, the health technology appraisal body for England and Wales, says it will recommend Amgen's thrombopoietin receptor agonist Nplate (romiplostim) for some patients with chronic idiopathic thrombocytopenic purpura (ITP). The turnaround comes after Amgen submitted a revised economic model and a patient access scheme to the institute.